Coherus BioSciences (CHRS) Misses Q2 EPS by 8c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.30 --0%
Revenue Growth %: +37.8%
Financial Fact:
Net income/(loss): 17.77M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +37.8%
Financial Fact:
Net income/(loss): 17.77M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.34), $0.08 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $10.25 million versus the consensus estimate of $10.16 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
- Green Bridge Metals plans Phase 2 drill program in Minnesota
- Needham Reiterates Buy Rating on UiPath Inc. (PATH)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
